San Diego-based Leo Lens Pharma has developed a therapeutic contact lens (CL) for continuous delivery of bimatoprost to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

“The lens, LL-BMT1, has the potential to reduce the progression of glaucoma and the rate of vision loss in patients with glaucoma due to better patient compliance, less IOP fluctuation and reduced side effects compared to treatment with eye drops,” said Dan Myers, Leo Lens Pharma CEO.

The LL-BMT1 therapeutic lens was developed using Leo Lens’ MediPrint process, a proprietary printing technology which digitally prints bimatoprost onto the anterior surface of the contact lens, allowing a sustained, continuous release of the ophthalmic drug.

The drug-delivering contact lens will now be tested in a human clinical trial.